ASSESSMENT OF THE DYNAMICS OF THE INFLUENCE OF ANEMIA ON HEMATOLOGICAL AND PATHOGENETIC INDICATORS IN PATIENTS WITH RA AND CKD BEFORE AND AFTER TREATMENT
Keywords:
anemia, rheumatoid arthritis, chronic kidney diseaseAbstract
Anemia is a common complication of rheumatoid arthritis (RA) and chronic kidney disease (CKD), significantly worsening the quality of life of patients. The aim of the study was to assess the dynamics of the effect of anemia on hematological and pathogenetic parameters in patients with RA and CKD before and after treatment. An analysis of existing studies devoted to this problem was conducted. Data on the effect of anemia on various hematological parameters (hemoglobin level, erythrocytes, etc.) and pathogenetic mechanisms (inflammation, endothelial dysfunction) in patients with RA and CKD were systematized. Correction of anemia in patients with RA and CKD leads to improvement of clinical symptoms, normalization of hematological parameters and reduction of the activity of the inflammatory process. Treatment of anemia also helps to slow down the progression of the underlying disease and reduce the risk of complications.
References
1. Anemia of chronic diseases: features of pathogenesis and possibilities of therapeutic correction (review of literature and results of own research) / V. T. Sakhin, E. R. Madzhanova, E. V. Kryukov [et al.] // Oncohematology. - 2018. - Vol. 13, No. 1. - P. 45-53.
2. Arutyunov, G. P. Anemia in patients with CHF / G. P. Arutyunov // Heart failure. - 2003. - V. 4, No. 5. - P. 224-227.
3. Blindar, V. N. Anemic syndrome and the main metabolites of ferrokinetics (ferritin, soluble transferrin receptor, prohepcidin, hepcidin-25 and endogenous erythropoietin) / V. N. Blindar, G. N. Zubrikhina, I. I. Matveeva // Medical alphabet. - 2015. - V. 2, No. 8. - P. 16-19.
4. Hepcidin as a regulator of iron homeostasis / A. A. Levina, T. V. Kazyukova, N. V. Tsvetaeva [et al.] // Pediatrics. - 2007. - V. 87, No. 1. - P. 67–74.
5. JL Babitt, MF Eisenga, VH Haase, et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference Kidney Int, 99 (2021), pp. 1280-1295
6. Julian BA Treatment of IgA nephropathy / BA Julian // Semin. Nephrol. -2000. - Vol. 20, No. 3. - P. 277-285.
7. Karstila K, Korpela M, Sihvonen S, Mustonen J. Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study. Clin Rheumatol . 2007;26(12):2089-2095.
8. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease Kidney Int Suppl, 2 (2012), pp. 279-335
9. Mori S, Yoshitama T, Hirakata N, Ueki Y. Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals. Clin Rheumatol 2017;36:2673e82.
10. Nagy J. Renal protection in IgA nephropathy requires strict blood pressure control / J. Nagy, I. Wittmann // Nephrology Dialysis Transplantation. - 2005. - Vol. 20, No. 8. - P. 1533-1539
11. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990e2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 2019;78:1463 e71
12. VH Haase Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease Kidney Int Suppl (2011), 11 (2021), pp. 8-25
